128 related articles for article (PubMed ID: 11081455)
21. Second-line, low-dose, weekly paclitaxel in patients with stage IIIB/IV nonsmall cell lung carcinoma who fail first-line chemotherapy with carboplatin plus paclitaxel.
Socinski MA; Schell MJ; Bakri K; Peterman A; Lee JH; Unger P; Yates S; Hudgens S; Kies MS
Cancer; 2002 Sep; 95(6):1265-73. PubMed ID: 12216094
[TBL] [Abstract][Full Text] [Related]
22. Weekly, high-dose paclitaxel in advanced lung carcinoma: a phase II study with pharmacokinetics by the Cancer and Leukemia Group B.
Akerley W; Herndon JE; Egorin MJ; Lyss AP; Kindler HL; Savarese DM; Sherman CA; Rosen DM; Hollis D; Ratain MJ; Green MR
Cancer; 2003 May; 97(10):2480-6. PubMed ID: 12733147
[TBL] [Abstract][Full Text] [Related]
23. Weekly paclitaxel as second-line chemotherapy for advanced or recurrent gastric cancer.
Hironaka S; Zenda S; Boku N; Fukutomi A; Yoshino T; Onozawa Y
Gastric Cancer; 2006; 9(1):14-8. PubMed ID: 16557431
[TBL] [Abstract][Full Text] [Related]
24. Low-dose weekly paclitaxel as second-line treatment for advanced non-small cell lung cancer: a phase II study.
Juan O; Albert A; Ordoño F; Casany R; Carañana V; Campos JM; Alberola V
Jpn J Clin Oncol; 2002 Nov; 32(11):449-54. PubMed ID: 12499416
[TBL] [Abstract][Full Text] [Related]
25. A phase II trial of paclitaxel and cisplatin in patients with advanced carcinoma of the esophagus.
Ilson DH; Forastiere A; Arquette M; Costa F; Heelan R; Huang Y; Kelsen DP
Cancer J; 2000; 6(5):316-23. PubMed ID: 11079171
[TBL] [Abstract][Full Text] [Related]
26. Phase II study of weekly paclitaxel in patients with non-small cell lung cancer who have failed previous treatments.
Yasuda K; Igishi T; Kawasaki Y; Kato K; Matsumoto S; Katayama S; Sako T; Shigeoka Y; Suyama H; Sugitani A; Yamamoto M; Hitsuda Y; Shimizu E
Oncology; 2004; 66(5):347-52. PubMed ID: 15331920
[TBL] [Abstract][Full Text] [Related]
27. Phase I/II study with paclitaxel in combination with weekly high-dose 5-fluorouracil/folinic acid in the treatment of metastatic breast cancer: an interim analysis.
Klaassen U; Wilke H; Pari CP; Strumberg D; Harstrick A; Eberhardt W; Becher R; Diergarten K; Seeber S
Semin Oncol; 1995 Dec; 22(6 Suppl 14):7-11. PubMed ID: 8553083
[TBL] [Abstract][Full Text] [Related]
28. Treatment of advanced adenocarcinomas of the exocrine pancreas and the gallbladder with 5-fluorouracil, high dose levofolinic acid and oral hydroxyurea on a weekly schedule. Results of a multicenter study of the Southern Italy Oncology Group (G.O.I.M.).
Gebbia V; Majello E; Testa A; Pezzella G; Giuseppe S; Giotta F; Riccardi F; Fortunato S; Colucci G; Gebbia N
Cancer; 1996 Sep; 78(6):1300-7. PubMed ID: 8826954
[TBL] [Abstract][Full Text] [Related]
29. Paclitaxel in the treatment of patients with upper gastrointestinal carcinomas.
Ajani JA; Ilson DH; Kelsen DP
Semin Oncol; 1996 Oct; 23(5 Suppl 12):55-8. PubMed ID: 8941411
[TBL] [Abstract][Full Text] [Related]
30. Second-line chemotherapy with 96-hour infusional paclitaxel in refractory non-small cell lung cancer: report of a phase II trial.
Socinski MA; Steagall A; Gillenwater H
Cancer Invest; 1999; 17(3):181-8. PubMed ID: 10099656
[TBL] [Abstract][Full Text] [Related]
31. A Phase I/II study of weekly paclitaxel and 3 days of high dose oral estramustine in patients with hormone-refractory prostate carcinoma.
Ferrari AC; Chachoua A; Singh H; Rosenthal M; Taneja S; Bednar M; Mandeli J; Muggia F
Cancer; 2001 Jun; 91(11):2039-45. PubMed ID: 11391583
[TBL] [Abstract][Full Text] [Related]
32. A phase II trial of nab-Paclitaxel as second-line therapy in patients with advanced pancreatic cancer.
Hosein PJ; de Lima Lopes G; Pastorini VH; Gomez C; Macintyre J; Zayas G; Reis I; Montero AJ; Merchan JR; Rocha Lima CM
Am J Clin Oncol; 2013 Apr; 36(2):151-6. PubMed ID: 22307213
[TBL] [Abstract][Full Text] [Related]
33. A phase II study of paclitaxel, weekly, 24-hour continous infusion 5-fluorouracil, folinic acid and cisplatin in patients with advanced gastric cancer.
Kollmannsberger C; Quietzsch D; Haag C; Lingenfelser T; Schroeder M; Hartmann JT; Baronius W; Hempel V; Clemens M; Kanz L; Bokemeyer C
Br J Cancer; 2000 Aug; 83(4):458-62. PubMed ID: 10945491
[TBL] [Abstract][Full Text] [Related]
34. Weekly 1-hour infusion of paclitaxel. Clinical feasibility and efficacy in patients with hormone-refractory prostate carcinoma.
Trivedi C; Redman B; Flaherty LE; Kucuk O; Du W; Heilbrun LK; Hussain M
Cancer; 2000 Jul; 89(2):431-6. PubMed ID: 10918176
[TBL] [Abstract][Full Text] [Related]
35. Aggressive simultaneous radiochemotherapy with cisplatin and paclitaxel in combination with accelerated hyperfractionated radiotherapy in locally advanced head and neck tumors. Results of a phase I-II trial.
Kuhnt T; Becker A; Pigorsch S; Pelz T; Bloching M; Passmann M; Lotterer E; Hänsgen G; Dunst J
Strahlenther Onkol; 2003 Oct; 179(10):673-81. PubMed ID: 14566475
[TBL] [Abstract][Full Text] [Related]
36. Phase I trial of docetaxel administered by weekly infusion in patients with advanced refractory cancer.
Hainsworth JD; Burris HA; Erland JB; Thomas M; Greco FA
J Clin Oncol; 1998 Jun; 16(6):2164-8. PubMed ID: 9626217
[TBL] [Abstract][Full Text] [Related]
37. Paclitaxel and carboplatin as first-line chemotherapy for advanced breast cancer.
Fountzilas G; Athanassiades A; Papadimitriou V; Dimopoulos MA; Bafaloukos D; Aravantinos G; Nicolaides C; Kalofonos H; Papakostas P; Xiros N; Razi E
Oncology (Williston Park); 1998 Jan; 12(1 Suppl 1):45-8. PubMed ID: 9516604
[TBL] [Abstract][Full Text] [Related]
38. Weekly 1-h paclitaxel infusion in patients with recurrent endometrial cancer: a preliminary study.
Nishio S; Ota S; Sugiyama T; Matsuo G; Kawagoe H; Kumagai S; Ushijima K; Nishida T; Kamura T
Int J Clin Oncol; 2003 Feb; 8(1):45-8. PubMed ID: 12601542
[TBL] [Abstract][Full Text] [Related]
39. Phase I evaluation of continuous 5-fluorouracil infusion followed by weekly paclitaxel in patients with advanced or recurrent gastric cancer.
Kondo K; Kobayashi M; Kojima H; Hirabayashi N; Kataoka M; Araki K; Matsui T; Takiyama W; Miyashita Y; Nakazato H; Nakao A; Sakamoto J
Jpn J Clin Oncol; 2005 Jun; 35(6):332-7. PubMed ID: 15961435
[TBL] [Abstract][Full Text] [Related]
40. Single-agent paclitaxel in the treatment of advanced non-small cell lung cancer.
Socinski MA
Oncologist; 1999; 4(5):408-16. PubMed ID: 10551557
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
